Aurigny hopes to submit its proposal in February, while the Chair of Alderney's Economic Development Committee says air links ...
Truist raised the firm’s price target on Protagonist Therapeutics (PTGX) to $110 from $88 and keeps a Buy rating on the shares. 2026 is expected ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果